» Articles » PMID: 24886641

Switching and Emergence of CTL Epitopes in HIV-1 Infection

Abstract

Background: Human Leukocyte Antigen (HLA) class I restricted Cytotoxic T Lymphocytes (CTLs) exert substantial evolutionary pressure on HIV-1, as evidenced by the reproducible selection of HLA-restricted immune escape mutations in the viral genome. An escape mutation from tyrosine to phenylalanine at the 135th amino acid (Y135F) of the HIV-1 nef gene is frequently observed in patients with HLA-A*24:02, an HLA Class I allele expressed in ~70% of Japanese persons. The selection of CTL escape mutations could theoretically result in the de novo creation of novel epitopes, however, the extent to which such dynamic "CTL epitope switching" occurs in HIV-1 remains incompletely known.

Results: Two overlapping epitopes in HIV-1 nef, Nef126-10 and Nef134-10, elicit the most frequent CTL responses restricted by HLA-A*24:02. Thirty-five of 46 (76%) HLA-A*24:02-positive patients harbored the Y135F mutation in their plasma HIV-1 RNA. Nef codon 135 plays a crucial role in both epitopes, as it represents the C-terminal anchor for Nef126-10 and the N-terminal anchor for Nef134-10. While the majority of patients with 135F exhibited CTL responses to Nef126-10, none harboring the "wild-type" (global HIV-1 subtype B consensus) Y135 did so, suggesting that Nef126-10 is not efficiently presented in persons harboring Y135. Consistent with this, peptide binding and limiting dilution experiments confirmed F, but not Y, as a suitable C-terminal anchor for HLA-A*24:02. Moreover, experiments utilizing antigen specific CTL clones to recognize endogenously-expressed peptides with or without Y135F indicated that this mutation disrupted the antigen expression of Nef134-10. Critically, the selection of Y135F also launched the expression of Nef126-10, indicating that the latter epitope is created as a result of escape within the former.

Conclusions: Our data represent the first example of the de novo creation of a novel overlapping CTL epitope as a direct result of HLA-driven immune escape in a neighboring epitope. The robust targeting of Nef126-10 following transmission (or in vivo selection) of HIV-1 containing Y135F may explain in part the previously reported stable plasma viral loads over time in the Japanese population, despite the high prevalence of both HLA-A*24:02 and Nef-Y135F in circulating HIV-1 sequences.

Citing Articles

A multi-epitope self-amplifying mRNA SARS-CoV-2 vaccine design using a reverse vaccinology approach.

Claudia B, Nugrahapraja H, Giri-Rachman E Res Pharm Sci. 2024; 19(5):520-548.

PMID: 39691299 PMC: 11648349. DOI: 10.4103/RPS.RPS_91_23.


Multimodal single-cell analyses of peripheral blood mononuclear cells of COVID-19 patients in Japan.

Kashima Y, Mizutani T, Nakayama-Hosoya K, Moriyama S, Matsumura T, Yoshimura Y Sci Rep. 2023; 13(1):1935.

PMID: 36732528 PMC: 9893982. DOI: 10.1038/s41598-023-28696-9.


Sterile alpha motif and histidine-aspartic acid domain-containing protein 1 expression and its relationship with T cell activation in human immunodeficiency virus/acquired immune deficiency syndrome patients with lung-spleen deficiency syndrome....

Zhen L, Qingyan Z, Bowen D, Feng S, Danni W, Ning K J Tradit Chin Med. 2022; 42(3):451-457.

PMID: 35610016 PMC: 9924747. DOI: 10.19852/j.cnki.jtcm.20220408.004.


Sustainable Antiviral Efficacy of Rejuvenated HIV-Specific Cytotoxic T Lymphocytes Generated from Induced Pluripotent Stem Cells.

Miki S, Kawai Y, Nakayama-Hosoya K, Iwabuchi R, Terahara K, Tsunetsugu-Yokota Y J Virol. 2022; 96(6):e0221721.

PMID: 35107374 PMC: 8941871. DOI: 10.1128/jvi.02217-21.


A Placebo-Controlled, Double-Blind Randomized (Phase IIB) Trial of Oral Administration with HPV16 E7-Expressing , GLBL101c, for the Treatment of Cervical Intraepithelial Neoplasia Grade 2 (CIN2).

Ikeda Y, Adachi K, Tomio K, Eguchi-Kojima S, Tsuruga T, Uchino-Mori M Vaccines (Basel). 2021; 9(4).

PMID: 33915901 PMC: 8066592. DOI: 10.3390/vaccines9040329.


References
1.
Winn M, Ballard C, Cowtan K, Dodson E, Emsley P, Evans P . Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr. 2011; 67(Pt 4):235-42. PMC: 3069738. DOI: 10.1107/S0907444910045749. View

2.
Allen T, Yu X, Kalife E, Reyor L, Lichterfeld M, John M . De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection. J Virol. 2005; 79(20):12952-60. PMC: 1235830. DOI: 10.1128/JVI.79.20.12952-12960.2005. View

3.
Brumme Z, Brumme C, Heckerman D, Korber B, Daniels M, Carlson J . Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog. 2007; 3(7):e94. PMC: 1904471. DOI: 10.1371/journal.ppat.0030094. View

4.
Cole D, Rizkallah P, Gao F, Watson N, Boulter J, Bell J . Crystal structure of HLA-A*2402 complexed with a telomerase peptide. Eur J Immunol. 2005; 36(1):170-9. DOI: 10.1002/eji.200535424. View

5.
Haas G, Plikat U, Debre P, Lucchiari M, Katlama C, Dudoit Y . Dynamics of viral variants in HIV-1 Nef and specific cytotoxic T lymphocytes in vivo. J Immunol. 1996; 157(9):4212-21. View